Welcome to our dedicated page for CARDIOGENICS HLDGS news (Ticker: CGNH), a resource for investors and traders seeking the latest updates and insights on CARDIOGENICS HLDGS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CARDIOGENICS HLDGS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CARDIOGENICS HLDGS's position in the market.
CardioGenics Holdings announced a new record date of October 8, 2021, for distributing 22.5 million shares of Covidgenic, a private Canadian company. This follows the previous record date of September 13, 2021. Shareholders seeking detailed information or updates are directed to visit www.cardiogenics.com or contact info@cardiogenics.com.
CardioGenics Holdings announced a dividend distribution of 22.5 million shares of Covidgenics, set for September 13, 2021. A new record date will be disclosed after meeting regulatory requirements. The company specializes in immunoassay technology targeting in-vitro diagnostics, with its QL Care Analyzer capable of running over 200 diagnostic tests. Key innovations include a proprietary silver coating method for enhancing instrument sensitivity.
CardioGenics Holdings (OTC PINK: CGNH) announced a 10-year global licensing agreement with Covidgenics Corp., granting exclusive rights to its QL Care Analyzer technology. CardioGenics will receive a 40% royalty on net sales and an additional 40% of non-royalty income from products developed by Covidgenics, along with 22.5 million shares of Covidgenics. To benefit shareholders, CardioGenics plans to distribute these shares as a dividend, effective September 13, 2021, on a pro rata basis.
FAQ
What is the market cap of CARDIOGENICS HLDGS (CGNH)?
